Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Rev Neurol (Paris) ; 180(7): 608-614, 2024 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-38431497

RESUMO

BACKGROUND: Left ventricular thrombus (LVT) is a source of cardiogenic embolic stroke. Conflicting data exist in the literature regarding the utilization of intravenous thrombolysis (IVT) at the acute phase of stroke in presence of LVT. We sought to assess the efficacy and safety of reperfusion therapies (IVT and/or thrombectomy) in patients with LVT. METHODS: We retrospectively analyzed patients with acute ischemic stroke and proven LVT and divided them in two groups: an intervention group with patients treated by reperfusion therapies and a control group with untreated patients. RESULTS: Between 2009 and 2021, 3890 patients were treated by reperfusion therapies in the Lyon stroke center, 33 of whom (0.9%) had LVT. We identified 27 control patients. There were more embolic recurrences at six months in the intervention group than in the control group (nine recurrences versus three, P=0.03, OR=13.56, 95% CI [1.5;195]). Only two early embolic recurrences (< 24h) occurred, both in the IVT group. There was a 4.8-fold decrease in the median NIHSS score between baseline and 24h follow-up in the intervention group (P<0.0001), and the two groups exhibited similar six-month mortality. At stroke onset, cardiopathy was known in 70% of patients, while LVT was known in 30%. CONCLUSION: Acute reperfusion therapies seem to be effective in the context of stroke in patients with LVT. However, further studies are needed to support the hypothesis that stroke recurrence might be related to the use of IVT.


Assuntos
Ventrículos do Coração , AVC Isquêmico , Reperfusão , Trombose , Humanos , Estudos Retrospectivos , Masculino , Feminino , AVC Isquêmico/terapia , AVC Isquêmico/complicações , Idoso , Pessoa de Meia-Idade , Trombose/etiologia , Trombose/epidemiologia , Trombose/terapia , Resultado do Tratamento , Reperfusão/métodos , Idoso de 80 Anos ou mais , Estudos de Coortes , Terapia Trombolítica/métodos , Cardiopatias/complicações , Cardiopatias/epidemiologia , Trombectomia/métodos , Recidiva
2.
Rev Neurol (Paris) ; 172(6-7): 389-91, 2016.
Artigo em Inglês | MEDLINE | ID: mdl-27180005

RESUMO

We describe a patient with SPG11 hereditary spastic paraplegia (HSP), who developed walking disorder in childhood. He presented three episodes of subacute gait disorders worsening between the age of 20 and 22 years. Brain and spinal MRI revealed multiple T2 hypersignal lesions, consistent with inflammatory lesions. Surprisingly, CSF analysis showed neither oligoclonal bands nor increased IgG index. He was dramatically improved by intravenous methylprednisolone. A relapsing-remitting multiple sclerosis (MS) was suspected. This is the first description of SPG11 HSP associated with MS.


Assuntos
Esclerose Múltipla/complicações , Esclerose Múltipla/genética , Proteínas/genética , Paraplegia Espástica Hereditária/complicações , Administração Intravenosa , Transtornos Neurológicos da Marcha/complicações , Transtornos Neurológicos da Marcha/diagnóstico , Transtornos Neurológicos da Marcha/tratamento farmacológico , Transtornos Neurológicos da Marcha/genética , Humanos , Masculino , Metilprednisolona/administração & dosagem , Esclerose Múltipla/tratamento farmacológico , Mutação , Paraplegia Espástica Hereditária/tratamento farmacológico , Paraplegia Espástica Hereditária/genética , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA